Allspring Global Investments Holdings LLC Has $56.46 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Allspring Global Investments Holdings LLC lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,824,127 shares of the company’s stock after selling 114,603 shares during the period. Allspring Global Investments Holdings LLC owned 0.16% of Teva Pharmaceutical Industries worth $56,457,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Grove Bank & Trust increased its position in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the period. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $41,000. Cromwell Holdings LLC raised its stake in Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares in the last quarter. Rothschild Investment LLC boosted its holdings in Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after purchasing an additional 1,348 shares during the period. Finally, JFS Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on TEVA shares. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. The Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Truist Financial boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Jefferies Financial Group upped their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Stock Up 0.5%

NYSE TEVA opened at $30.26 on Thursday. The business has a fifty day moving average price of $32.22 and a two-hundred day moving average price of $27.63. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The stock has a market capitalization of $34.79 billion, a PE ratio of 25.21, a PEG ratio of 10.15 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter last year, the business posted $0.71 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the sale, the insider directly owned 10,914 shares of the company’s stock, valued at $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares in the company, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 920,901 shares of company stock worth $30,056,789 over the last quarter. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.